Almac will analyse samples taken during European trials of an infused version of irinotecan, 5-fluorouracil and folinic acid in patients with advanced colorectal cancer to identify biomarkers, drug targets and patients for whom the regimen is most beneficial.
Paul Harkin, president of Almac’s diagnostics unit, explained that: “As understanding grows of the heterogeneity of cancer, it is becoming increasingly clear that molecular subtypes are important both in patients’ prognosis and in predicting their response to chemotherapy.
“This has already been shown in breast cancer, and the study to be led by Almac, Pfizer and PTRW aims to examine this in colorectal cancer.”
